Clinical Trials FAQ

  • What does it cost to participate? There is no cost to participate.
  • Where do the visits take place? Visits take place at our Clinical Translational Research Center in Hewitt Hall on the UC Irvine campus in Irvine.
  • How long are the visits? On average, a visit can last between 1-2 hours.
  • Do I need to stop taking my current medications to participate?  No, you can continue on your current medications. However, many trials require that dosages have been stable for 2 to 4 months prior to enrolling.
  • Will I be given any feedback on the results of the study?  Yes. Some studies provide participants with copies of their clinical lab results, EKG tracings, and brain imaging reports.
  • Will I be notified about the results of the study?  Most studies provide participants with a summary of results once they are available.  Studies also generally inform participants of their study assignment (study drug vs. placebo) after there is no longer risk of biasing study results.
  • Will there be compensation for my participation?  Some studies do provide compensation, but it varies from study to study.
  • Why should I participate in a clinical trial?  Most people choose to participate in clinical trials for three reasons: (1) hope to help mankind; (2) trust in the researchers; (3) hope for personal benefit.
  • Where can I find out more information about clinical trials?  You can contact our Clinical Trials Recruitment Coordinators at (949) 824-0008 or by email,
  • Is there a chance of getting a placebo during the trial?  In most studies, a portion (e.g. 50%) of the participants are given placebo. This varies from study to study and is critical to the scientific aims of a study.
  • Are there any studies that are not double-blind?  The majority of our studies are double-blind, meaning both the investigator and the participant do not know whether drug or placebo is being given. On some occasions we do conduct open label studies in which all participants receive the actual study medication. These studies, however, are usually restricted to those individuals who previously completed the double-blind study of the same medication.